Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Sandler

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 2010
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation studyFrancisco Robert, Alan Sandler, Joan H Schiller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancerPhilip E Lammers, Yu Shyr, Chung-I Li, et al.
Clinical Lung Cancer|July 19, 2018
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung CancerRodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler, Athanassios Argiris, Jyoti D Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II studyJoan H Schiller, Timothy Larson, S-H Ignatius Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancerNasser Hanna, Paul A Bunn, Corey Langer, et al.
Gastrointestinal Endoscopy|August 28, 2002
Clinical utility of EUS-guided fine-needle aspiration of mediastinal masses in the absence of known pulmonary malignancyBenedict M Devereaux, Julia Kim Leblanc, Edward Yousif, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancyAlan Sandler, Michael Gordon, Dinesh P De Alwis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor KineticsLaurent Claret, Jin Y Jin, Charles Ferté, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2009
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabDavid P Carbone, J Stuart Salmon, Dean Billheimer, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|January 1, 2010
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation studyFrancisco Robert, Alan Sandler, Joan H Schiller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancerPhilip E Lammers, Yu Shyr, Chung-I Li, et al.
Clinical Lung Cancer|July 19, 2018
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung CancerRodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler, Athanassios Argiris, Jyoti D Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II studyJoan H Schiller, Timothy Larson, S-H Ignatius Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancerNasser Hanna, Paul A Bunn, Corey Langer, et al.
Gastrointestinal Endoscopy|August 28, 2002
Clinical utility of EUS-guided fine-needle aspiration of mediastinal masses in the absence of known pulmonary malignancyBenedict M Devereaux, Julia Kim Leblanc, Edward Yousif, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancyAlan Sandler, Michael Gordon, Dinesh P De Alwis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor KineticsLaurent Claret, Jin Y Jin, Charles Ferté, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2009
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabDavid P Carbone, J Stuart Salmon, Dean Billheimer, et al.
Pageof 9